

# 16<sup>th</sup> GLOBAL ANNUAL ONCOLOGISTS MEETING

April 24-25, 2017 Dubai, UAE



## *Sadir Alrawi*

*Alzahra Cancer Center, Dubai*

### **Updates of HIPEC in colorectal carcinomatosis: Principals and review**

Colorectal growth patients with peritoneal metastases (PM) are generally accepted to have poor guess, which shows it is of no incentive to receive surgical treatment and that idea was old. With the progression of surgical methods, hyperthermic intraperitoneal, chemotherapy (HIPEC) and with various modalities of chemotherapy imbue ment multidisciplinary treatment as of late, the comprehension and treatment systems of colorectal peritoneal metastases (CPM) have changed drastically. As far as forecast, CPM under the palliative systemic treatment demonstrates a substandard result contrasted and nonperitoneal metastasis. By and by, some CPM patients managable to the total peritoneal cytoreductive surgery (CRS) joined with HIPEC may accomplish long haul survival. The prognostic components of CPM contain peritoneal carcinomatosis file (PCI), culmination of cytoreduction score (CC score), the nearness of extraperitoneal metastasis (liver, and so forth.), peritoneal surface illness seriousness score (PSDSS) and Japanese peritoneal arranging. Taken together, writing information propose that a multimodality approach consolidating complete peritoneal CRS in addition to HIPEC, systemic chemotherapy, and focused on treatment might be the best treatment alternative for PM from colorectal growth. We are attempting to show the significance of HIPEC in colorectal malignancy and different tumors.

### **Biography**

Sadir Alrawi is currently the Director of all Surgical Oncology Services at Alzahra Cancer Center in the heart of Dubai and its tertiary referral cancer center for all UAE, hosting highly specialized surgical oncology subspecialties, including Colorectal, Breast Oncology, Head & Neck Surgery, Urology, Gynecological Oncology, Sarcoma/Melanoma and Peritoneal Surface Malignancy, in addition to Pancreatic and Hepatic Surgery. He is currently working as a Professor at John Hopkins medical system. He served as the Chief of Surgical Oncology Division at Tawam Hospital and was Interim Chair of Department of Surgery from October 2013-September 2015. His major interest is in Gastrointestinal Oncology, including esophageal, gastric, pancreas, liver and colonic surgery with special interest in endocrine surgery including thyroid, parathyroid and adrenal surgery.

[Sadir.AlRawi@azhd.ae](mailto:Sadir.AlRawi@azhd.ae)

### **Notes:**